Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate
Launched by HK INNO.N CORPORATION · Apr 30, 2013
Trial Information
Current as of May 25, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Male volunteers in the age between 20 and 55 years old(inclusive)
- • Body mass index (BMI) in the range of 18.5 to 27 kg/m2(inclusive)
- • Available for the entire study period
- • Understand the requirements of the study and voluntarily consent to participate in the study
- Exclusion Criteria:
- • Subjects with a history of gastrointestinal diseases which might significantly change ADME of medicines
- • Systolic blood pressure outside the range of 100 to 150 mmHg or diastolic blood pressure outside the range of 60 to 1000 mmHg for male subjects. when screening period
- • Subject with symptoms of acute disease within 14days prior to study medication dosing
- • Subjects with a history of clinically significant allergies
- • Subjects with a hereditary problems, for example, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- • Subjects whose clinical laboratory test values are outside the accepted normal range(Especially,AST or ALT \>1.5 times to normal range or total bilirubin \> 1.5times to normal range)
- • History of drug abuse
- • History of caffeine, alcohol, smoking abuse
- • caffeine(coffee,tea,coke) or grapefruit juice \> 4cups/day
- • smoking \> 20 cigarettes/day
- • alcohol \> 140g/week
- • Positive test results for HBs Ab, HCV Ab, Syphilis regain test
- • Participation in any clinical investigation within 30days prior to study medication dosing
- • Subjects with whole blood donation within 60days, component blood donation within 30days and blood transfusion within 30days prior to study medication dosing
- • Subjects considered as unsuitable based on medical judgement by investigators
About Hk Inno.N Corporation
hk inno.n corporation is a pioneering biopharmaceutical company dedicated to advancing innovative therapies that address unmet medical needs. With a strong focus on research and development, the company leverages cutting-edge technologies and scientific expertise to create novel treatment solutions across various therapeutic areas. Committed to high standards of clinical excellence and patient safety, hk inno.n collaborates with leading research institutions and healthcare professionals to drive the progress of its clinical trials, aiming to enhance patient outcomes and contribute to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Jae-wook Ko, MD, PhD
Principal Investigator
Samsung Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials